The Globe and Mail reports in its Saturday edition that drug makers including Pfizer, Sanofi SA and Takeda plan to raise prices in the United States on more than 500 drugs in early January, according to data analyzed by health care research firm 3 Axis Advisors. A Reuters dispatch to The Globe says that excluding different doses and formulations, more than 140 brands of drugs will have their prices raised next month, the data show. The expected price increases come as the pharmaceutical industry gears up for the Biden administration to publish significantly discounted prices for 10 high-cost drugs in September, and continues to contend with inflated manufacturing costs. Under President Joe Biden's Inflation Reduction Act (IRA), the government's Medicare health program can negotiate prices directly for some drugs starting in 2026. Worries are also growing about fresh disruption to supply chains from shippers forced to halt or reroute traffic from the Red Sea, the world's main East-West trade route. Three companies including GlaxoSmithKline, which recently said it would cut prices on some asthma, herpes and anti-epileptic drugs for 2024, are expected to lower prices on at least 15 drugs in January, according to the data.